The primary objective of this study is to induce the generation of Tregs from CD4+ T cells by using Aza in vitro, followed by the intravenous infusion of induced Tregs (iTregs) to treat atherosclerosis, in order to elucidate the underlying mechanisms involved. This evidence concerns the gene CD4 and atherosclerosis.